Artal Group S.A. Chinook Therapeutics, Inc. Transaction History

Artal Group S.A.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$21.53 - $26.8 $5.57 Million - $6.93 Million	258,687 New	258,687 $5.99 Million
Q1 2022 May 12, 2022	SELL	$12.02 - $16.69 $2.17 Million - $3.01 Million	-180,500 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$11.9 - $20.91 $2.15 Million - $3.77 Million	180,500 New	180,500 $2.86 Million

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.